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Objectives: Hemophilia is a sex-linked condition affecting about 1 of every 5000 males in the United States. The
management of children with hemophilia can be improved with regular intravenous infusion of factor VIII or IX, thus
preventing crippling and sometimes fatal hemorrhage. Maintaining this vital intravenous access is often hampered by
gradual loss of superficial veins or repeated central catheter sepsis and thrombosis. This study reviewed an experience with
arteriovenous fistula in selected hemophilia patients with limited venous access.
Methods:Consecutive patients operated on between October 2000 and July 2006 for venous access with the creation of an
arteriovenous fistula were reviewed. They were selected because of repeated problems with other venous access. Patency,
ease of use, duplex scan derived brachial artery diameter, and arm length were assessed.
Results: During a 69-month period, 10 arteriovenous fistulas (five brachial artery-basilic vein fistulas, 5 brachial
artery-cephalic vein fistulas) were created for nine patients. The patients were a median age of 5.5 years (range, 1 to 27
years), and all were <13 except the 27-year-old patient. There were no postoperative hematomas requiring evacuation.
One arteriovenous fistula failed to mature and was redone in the opposite arm, which subsequently occluded after 13
months. Of the mature fistulas, patency was 100% at 1 year, 80% (4/5) at 3 years, and 75% (3/4) at 4 years, with mean
follow-up of 22 months. Brachial artery diameter increased in the involved arm by a ratio of 1.95 (range, 1.51 to 2.5)
compared with the opposite arm. Arm length disparity was increased by 0.5 cm (range, 0.8 to 1.5 cm) in the involved arm.
All fistulas allowed good access at home by a care provider.
Conclusions: For hemophilia patients with compromised venous access, arteriovenous fistulas provide good early patency.
Brachial artery diameter and arm length require continued follow-up. (J Vasc Surg 2007;45:986-91.)Hemophilia is a congenital, sex-linked bleeding disorder
caused by the lack of coagulation factor VIII (hemophilia A)
or IX (hemophilia B) and results in a life-long condition
effecting approximately 1 in 5000males. Before themiddle of
the 20th century, the disease was untreatable; however, the
symptoms of hemophilia can now be ameliorated with intra-
venous infusion of specific clotting factor concentrates. The
regular, scheduled use of factor concentrate before bleeding
occurs, referred to as prophylaxis, results in a reduction of
bleeding episodes and crippling joint disease.1,2 Since 1994,
theNational Hemophilia Foundation has recommended pro-
phylaxis as the optimal treatment for severe hemophilia.3
Prophylaxis may be prescribed once or more each week and
requires reliable intravenous access.4
The small size of the patient or repeated venipuncture
may eventually destroy peripheral veins, and many patients
require placement of a central venous access device, either
an external central venous catheter or a subcutaneous im-
planted port device.5,6 Ports have low visibility for children
but are time-consuming to use and expensive to place.7,8
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986External catheters are inconvenient and unpopular with
children.9 Both types of device are susceptible to infec-
tion,10,11 and venous thrombosis may also occur.
Although peripheral veins are the preferred route for
venous access, this is not always possible. As an alternative,
an arteriovenous fistula is a potentially attractive solution.
Once a fistula has matured, veins are easy to access quickly
and the cosmetic impact is usually low, with an equally low
rate of infection anticipated.
The use of an arteriovenous fistula for the treatment of
hemophilia has been reported. In 1974, Sussman and Loz-
man12 reported using an arteriovenous fistula to treat a
60-year-old patient with hemophilia. Goldenberg et al13
used polytetrafluoroethylene (PTFE) grafts for six adults
with hemophilia, reporting patency from 4 to 28 months in
1980. Use of arteriovenous fistula has been reported in chil-
dren to treat renal failure with hemodialysis as a bridge to
transplantation if peritoneal dialysis is not feasible. Small series,
including 24 children reported by Lumsden14 and 14 patients
reported by Guzzetta,15 document this experience.
Recently, a defining article by Santagostino et al16
reviewed 27 hemophilia patients (23 children and four
adults) all treated with an arteriovenous fistula beginning in
1999 in Milan, Italy. Knowing of their work and prompted
by their success, our center began using arteriovenous
fistulas in 2000 to treat selected children with hemophilia.
The following is a review of this experience.
METHODS
Patient selection. Candidates were selected from the
population of approximately 200 hemophilia patients cared
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beginning in January 2000. About two thirds of these
patients receive regular intravenous factor prophylaxis ther-
apy or require intravenous immune tolerance therapy. Im-
mune tolerance is a specialized therapy that addresses a
complication of hemophilia—the development of alloim-
mune antibodies or an inhibitor—and requires frequent
intravenous access.
About 80% of the treated patients are managed with
peripheral intravenous therapy, of whom 20% have failed
this method and have central catheters. Selected patients
were chosen if they had lost peripheral venous access and
had had repeated mechanical or infectious problems with
central venous access devices. The median number of cen-
tral venous catheter infections was three (range, 0 to 4).
Arteriovenous fistulas were not offered as a primarymeans
of venous access, except for one patient, but generally only to
those patients who had failed traditional methods. Parental
screening was of importance in that these caregivers would
need to be able to use the fistula for venous access at home.
Patients 18 months old were maintained with other
methods until they grew to a larger size to allow a higher
likelihood of surgical success. The algorithm used to rec-
ommend an arteriovenous fistula generally followed this
sequence: peripheral veins were used first, central venous
catheter access next, and then recommendation for an
arteriovenous fistula after infection of the central venous
access.
Surgical evaluation. After an initial screening by the
hematologist (L. A. V.), patients were referred for surgical
consultation. Again, the patient’s psychologic profile and
parental or caregiver support were assessed. The patient’s
dominant arm was determined so that fistulas could be
placed, if possible, on the nondominant side. Physical ex-
amination documented radial, ulnar, and brachial pulses,
but often, the cephalic and basilic veins were not palpable
or visible even with a tourniquet. Some children had fore-
arm fasciotomy sites or significant contraction of their
elbow joints from previous bleeding episodes, and these
were considered in planning the fistula location.
All of the patients were carefully evaluated both preop-
eratively and postoperatively with duplex ultrasound imag-
ing. Duplex ultrasound with a 10-MHz probe was used to
map the veins of the upper extremity. Preoperatively, the
deep system veins were examined for patency and stenosis,
including the internal jugular veins, innominate, subcla-
vian, axillary, and brachial veins. The patency and diameter
of the cephalic and basilic veins were assessed at the proxi-
mal, mid, and distal extremity. None of the patients were
excluded because of central venous thrombosis or stenosis.
Brachial artery Doppler waveforms were obtained to ensure
adequate inflow for the fistula. No major arterial anomalies
or variations were identified.
After surgery, the inflow artery, the fistula, and the
outflow vein were assessed for stenosis, with a doubling of
velocity considered to indicate a significant stenosis. Aneu-
rysmal areas and the diameter of the brachial artery were
also measured. A ratio between the brachial artery diameterof the treated side and the nontreated side was calculated.
Depending on the patient’s age, the examinations were
somewhat limited owing to patient movement and cooper-
ation, but in every case, considerable useful information
was obtained. Cephalic and basilic veins 2 mm in diame-
ter were not used for fistula formation because it was
thought that veins of this caliber would be less likely to
mature and allow adequate access.
Hematologic management during surgery. Most
patients did not have functioning central venous access, and
the day of the planned surgical procedure, peripherally
inserted central catheters were placed in the opposite ex-
tremity for factor infusion. Treatment plans were individu-
alized, and the hematologist provided a written manage-
ment plan for use the day of the operation and during the
operation. Bolus therapy was used in some patients, and a
continuous infusion was preferred in others. The hematol-
ogist was available by phone to the operating room to
recommend additional therapies, depending on the assess-
ment of surgical bleeding during the operation.
Patients were cared for in the pediatric stepdown unit
after the surgical recovery room and were observed for
approximately 4 days before discharge. During the first 48
hours postoperatively, the patient’s coagulopathy was in-
tentionally under-corrected to promote fistula patency.
Patients were then fully corrected and the drains were
removed.
Surgical procedure. Because of small vein size, only
upper arm arteriovenous fistulas were created in this series,
and no radial artery–cephalic vein fistulas were used. The
larger of the basilic vein or cephalic vein above the antecu-
bital fossa was selected for end-to-side anastomosis with the
brachial artery. Given equal size, the cephalic vein was used
because it does not require mobilization to a more super-
ficial location in the subcutaneous tissue. Whenever the
basilic vein was used, it was mobilized and placed in a
superficial tunnel, created by careful finger and curved
6-inch clamp dissection over the anterior medial upper arm.
Systemic heparin anticoagulation was not used. Rather,
heparinized saline containing papaverine (60 mg/100 mL
of heparinized saline) was infused through a 20-gauge cathe-
ter proximally and distally into the brachial artery and proxi-
mally through the venous outflow before anastomosis.
The end (vein)-to-side (artery) anastomosis was com-
pleted with interrupted 7-0 or 8-0 polypropylene suture
using 2.5 loupe magnification. General anesthesia was
used for all patients. Subcutaneous skin closure was used for
a better immediate cosmetic effect. Wounds were closed
over a 7F silastic suction drain, and an arm splint was placed
for the first few postoperative days in an attempt to mini-
mize postoperative bleeding complications.
Fistulas were allowed to mature for 6 to 8 weeks
before being injected. In some cases, the location of the
vein to be injected was outlined with an indelible marker
to assist the caregiver with the first few treatments. Once
mature, the fistulas were accessed daily by two patients,
three times weekly by five patients, and twice weekly by
two patients.
rosis
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visualize the fistula at the time of the first postoperative visit
and every 3 months thereafter for a year. Subsequent du-
plex surveillance was conducted annually thereafter. Pa-
tency was documented by physical examination, success of
fistula injections, and duplex scanning and was expressed as
a percentage of those patent compared with those at risk.
After 6 to 8 weeks, the patient’s caregiver was taught
the technique of fistula injection in the hematology office.
Once the caregiver was deemed capable of doing this safely,
therapy was initiated through the fistula with a frequency
determined by the individual’s needs. Butterfly sets with a
hand-held 3 mL syringe or 25-gauge needles were used.
Wrist pulses distal to the fistula were assessed on office
visits, and parents and patients were questioned about hand
symptoms. The arm length was measured, with the patient
standing, from the tip of the middle finger to the sternal
notch of the right and left arm.
RESULTS
The patient characteristics are outlined in Table I,
along with some of the preoperative comorbidities and
postoperative complications. None of the patients had the
comorbidities usually seen in arteriovenous fistula cohorts
for dialysis access such as diabetes, hypertension, hypercho-
lesterolemia, or smoking. The youngest patient was 18
months old. The oldest, at 27 years old, had hemophilia B
and was confined to a wheel chair owing to recurrent
hemorrhage over many years. All others were 13 years
(median age, 5.5 years).
The arteriovenous fistulas were done during 69months
beginning in October 2000 and ending in July 2006. Five
were brachial artery-to-basilic vein fistulas and five were
brachial artery-to-cephalic vein fistulas. One of the cephalic
vein fistulas was constructed using the median cubital vein
such that retrograde flow was possible and the forearm
veins also dilated.
There was no postoperative mortality and there were
no hematomas that required evacuation, although one
patient did develop a palpable hematoma. A palpable radial
pulse was retained on the affected side after fistula place-
ment in all 10 cases. There were no deep wound infections.
Table I. Additional patient characteristics
Patient Age Sex Hemophilia condition
1 9 M A, inhibitor Multiple
2 7 M A, severe Cutaneou
3 2 M A, severe Soft tissu
4 6 M A, inhibitor Left arm
5 27 M B, inhibitor Hepatitis
graftin
6 1 M A, inhibitor Surgical b
7 11 M A, severe Multiple
8 13 M B, severe Morbid o
9 2 M A, inhibitor HemarthTwo patients had minor skin dehiscence with wound clo-sure by secondary intention. One of these dehiscences
involved a small hematoma.
All patients were available for postoperative follow-up
and are currently seen regularly in the Hematology Center,
except for one patient who now resides out-of-state. Tele-
phone reports from this patient’s hematologist indicate that
the fistula is currently working well for home injection. All
patent fistulas are currently being used without reported
difficulty by the patients’ parents or caregivers.
No hand ischemia has developed. One fistula failed to
mature and was successfully redone on the opposite arm.
This second fistula then occluded after 13 months of use
that included repeated injections of various medications
other than factor concentrate. Of the nine fistulas that
matured, patency was 100% at 1 year (7/7), 80% at 3 years
(4/5), and 75% at 4 years (3/4), with a mean follow-up of
22 months.
Brachial artery diameters were measured by duplex
scanning and the results are summarized in Table II. Five of
the nine patients had meaningful measurement. Of the
other four, one did not have a patent fistula, one hadmoved
out-of-state, and two had only 2 months of follow-up. Arm
length measurements were recorded for the same five indi-
viduals. It is apparent that if the arm length difference was
1 cm, the longer arm corresponds to the fistula side,
whereas with smaller differences, the longer arm is on the
non-operated on side.
An informal assessment of all 10 patients or their care-
givers indicates unanimous satisfaction with the fistula,
including the one patient in whom two fistulas were done.
Only one fistula, with retrograde flow into the forearm
veins, was not aesthetically satisfactory. The others fistulas
were entirely above the elbow, were not visible under
clothing, and unless the arm was exercised to increase local
blood flow, were barely visible upon inspection of the
undressed limb. The children were not inhibited by the
fistulas and did not appear to manifest any reservation or
reticence about them.
DISCUSSION
With the advent of intravenous recombinant factor
replacement to correct specific defects in hemophilia, ve-
Hemophilia complications
rthrosis including ankles with synovectomy
eding, arms
joint bleeding
eft leg fasciotomy, playmate had pulled out central catheter
emarthrosis, osteoarthritis, fasciotomy of arms; with skin
sonality disorder, anxiety, depression
ing, severe tongue bleeding










besitnous access is paramount. However, the trend for place-
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have been exhausted has waned recently owing to the risks
of infection or thrombosis, or both. Thus, a critical need for
venous access is what has driven the use of arteriovenous
fistulas for selected patients with hemophilia who require
frequent factor infusion. Interestingly, fistulas have also
been reported for reasons other than hemodialysis in the
past.17 However, little previous information exists related
to very small diameter autogenous arteriovenous fistulas in
children with hemophilia and our concerns in initiating our
program were twofold: would the fistulas remain patent for
a significant length of time and would there be any harm to
the children?
The fistula patency appears to be acceptable in that only
one of the mature fistulas has occluded during follow-up.
Thus, a 75% patency at 4 years does seem adequate to make
this procedure practical. By comparison, Lumsden et al14
included 15 arteriovenous fistulas in their 1994 report on
access construction for a pediatric dialysis population and
reported a mean functional patency duration of only 6.2
months; however, five of the 15 fistulas failed to mature.
Ten of the fistulas in their series were from the radial artery
to the cephalic vein, and some may have been unsuccessful
because of the extremely small vessel sizes of these fistulas.
As another consideration, the small size of the access needle
and the lower hemodynamic stress on the fistula when it
was not used for dialysis access may have contributed to the
superior patency rates in the present study compared with
those used for hemodialysis in series by Lumsden et al.
Other reasons for the superior patency in our studymay
be the hemophilia population’s distinctly different throm-
bogenic potential and the use of preoperative ultrasound
imaging to guide vein selection. In addition, the central
venous outflow was assured to be patent in every patient by
duplex ultrasound examination. Duplex mapping allowed
proximal stenoses in the veins being considered for fistula
construction to be avoided, because in many cases, these
veins had been used for peripheral venous access or previ-
ously punctured for peripherally inserted central catheter
placement.
In the series of Santagostino et al16 of 31 fistulas that
weremostly in childrenwith hemophilia, the patencywas 84%
with amean follow-up of 31months (range, 5 to 44months).
The choice of fistula location in that series from Milan was
Table II. Brachial artery diameters and arm measurement
Brachial artery
diameter (mm)
Patient Follow-up (months) Right Lef
9 65 3 6.
2 50 2.9 5.
4 37 3.6 5.
5 9 4.2 6.
6 7 2 5
*Treated side.radial-cephalic in 1, brachial-cephalic in 8, brachial-basilic in 3,and brachial-median cubital anastomosis in 19. The use of
more proximal anastomoses, almost all above the elbow, un-
doubtedly contributes to this good patency rate.
All of the fistulas in the present study were also per-
formed proximally in the arm, at or above the elbow.
Goldenberg et al13 also reported a mean patency of 20
months (range, 4 to 20 months) using PTFE grafts in six
adults with hemophilia, with six patients having function-
ing grafts at the time of publication. However, published
results have clearly demonstrated that prosthetic arterio-
venous grafts have inferior patency compared with autolo-
gous arteriovenous fistulas when used for hemodialysis
access.18 Hence, only autogenous tissue was used to con-
struct the arteriovenous fistulas in this study. Finally, Suss-
man and Lozman’s12 60-year-old hemophilia patient with
a radial artery-to-cephalic vein anastomosis was reported as
functioning well after 1 year at the time of publication.
In addition to patency, other potential concerns in the
construction of arteriovenous fistula in these young pa-
tients were perioperative morbidity, limb length abnormal-
ities, the potential for high output cardiac failure, and
significant arterial size increase. No significant periopera-
tive morbidity was associated with the 10 operations; how-
ever, three patients had measurable arm length differences
of 1, 1, and 1.5 cm after 7, 9, and 65 months, respectively.
Of interest was that in two other patients, the arm with the
fistula was found to be slightly shorter.
Limb length has been reported to be altered by a proximal
surgically placed arteriovenous fistulas by Guzzetta et al, 15
who reviewed the subject in pediatric dialysis patients. They
found that three of five patients with PTFE femoral artery-
to-femoral vein fistulas developed significant leg length
discrepancy and gait abnormalities requiring fistula liga-
tion. In contrast, none of the children with upper extremity
arteriovenous fistulas in that series were found to have arm
length abnormalities. Upper extremity length differences
are not as critical as with the lower extremity, but neverthe-
less, continued measurements will be made.
Guzzetta et al15 also noted that cardiac failure devel-
oped in one patient with a thigh PTFE fistula that required
fistula ligation. None of the nine patients in the present
series had any sign of heart failure, and all but the 27-year-
old patient are extremely active.
Because of increased flow, artery diameters are known
Arm length (cm)
Ratio Right Left* Difference
2.23 68 69.5 1.5
1.96 61 60.2 0.8
1.51 71.5 71 0.5
1.59 79 80 1





7to increase proximal to arteriovenous fistulas. These
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ing one arm with the other and measuring the brachial
artery diameter with duplex scanning. A ratio between
vessels of 2.23 was noted in the patient with the longest
follow-up, whose fistula had been functioning for 65
months. Other patients with shorter follow-up had similar
ratios, and we hope that this size change will stabilize.
Nevertheless, the children will be continued with periodic
duplex evaluation.
The exact indication for fistula placement in hemo-
philia patients for prophylactic factor infusion remains open
to debate. A national consensus conference in the United
States agreed that fistulas should be reserved for patients
who had undue difficulty with conventional central venous
access, usually related to catheter infection.5 This stance
conflicts somewhat with the policy at the University of
Milan, where Santagostino and colleagues16 use arterio-
venous fistulas as the first option for achieving permanent
venous access in children with severe hemophilia and poor
peripheral veins.
As confidence and published positive results accumu-
late, this policy may slowly change in North America.
However, currently it seems prudent to reserve fistula cre-
ation for patients unsuitable for or with complications from
central catheter access. A policy shift may be driven some-
what by the ease and reliability of fistula use, because once
the fistulas were mature, all of the present patients enjoyed
successful, sometimes daily, home use.
CONCLUSION
This clinical experience demonstrates that arterio-
venous fistulas can be successfully used to support children
with hemophilia who need intravenous prophylaxis with
factor infusion. The surgical procedure has low morbidity.
Success is likely enhanced by carefully selecting patients and
their parents and by preoperatively mapping the venous
conduit and outflow with duplex scanning. Fistula place-
ment in the arm at the elbow may increase patency because
the artery and vein are larger than at the wrist.
Thus far, we have selected patients for fistula construc-
tion who have failed conventional central venous catheter
use. However, high acceptance rates by patients and their
parents may liberalize these indications if good long-term
patency is consistent and complications rates remain low.
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Dr William Turnipseed. Just a comment. I think this idea is fistulas for uses besides dialysis. I just anecdotally have two patients
that were referred to me when I first came to the VA before we had
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Volume 45, Number 5 McCarthy et al 991liver transplant as part of our program. The patient had recurrent
esophageal variocele bleeding and required transfusions almost
every two weeks. We put an AV fistula in him, a brachiocephalic
fistula that lasted 15 years until he had a new liver transplanted. Therequired multiple transfusions over years and lacked venous access.
I think your concept is an applicable one, not only to this unique
group of individuals but also to others where curative technologies
do not apply.other patient had an AVmalformation of the nasopharynx that had Dr Goncharova. Thank you.
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